Review
Copyright ©2014 Baishideng Publishing Group Inc. All rights reserved.
World J Clin Infect Dis. Nov 25, 2014; 4(4): 41-49
Published online Nov 25, 2014. doi: 10.5495/wjcid.v4.i4.41
DNA methylation in liver diseases
Shuai Gao, Kai Wang
Shuai Gao, Kai Wang, Department of Hepatology, Qilu Hospital of Shandong University, Jinan 250012, Shandong Province, China
Kai Wang, Institute of Hepatology, Shandong University, Jinan 250012, Shandong Province, China
Author contributions: Gao S and Wang K contributed to this paper.
Supported by Grants from Key Project of Chinese Ministry of Science and Technology, No. 2012ZX10002007, 2013ZX10002001; National Natural Science Foundation of China, No. 81171579, 81201287; Science and Technology Development Plan of Shandong Province, No. 2012GSF11846
Correspondence to: Kai Wang, MD, PhD, Department of Hepatology, Qilu Hospital of Shandong University, Wenhuaxi Road 107#, Jinan 250012, Shandong Province, China. wangdoc876@126.com
Telephone: +86-531-82169596 Fax: +86-531-86927544
Received: June 27, 2014
Revised: July 24, 2014
Accepted: October 1, 2014
Published online: November 25, 2014
Core Tip

Core tip: This review summarized recent progress of DNA methylation study and provided an overview of DNA methylation and liver diseases. The association between DNA methylation and liver diseases including hepatocellular carcinoma, liver fibrosis, nonalcoholic steatohepatitis or liver failure were extensively discussed. We also discussed the potential of DNA methylation as biomarkers and therapeutic targets for liver diseases. This review aimed to provide the emerging DNA methylation information about liver diseases. It might provide essential information for managing and care of these patients.